LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $95.25.

Several brokerages have commented on LMAT. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Lake Street Capital lifted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC lifted its holdings in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its position in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV raised its stake in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares during the last quarter. Huntington National Bank boosted its holdings in LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 455 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $150,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $85.16 on Wednesday. LeMaitre Vascular has a 52 week low of $62.39 and a 52 week high of $109.58. The firm has a 50-day moving average price of $92.47 and a two-hundred day moving average price of $94.36. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 46.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, sell-side analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a $0.20 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.